VIGIL NEUROSCIENCE INC. - COMMON STOCK

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

08 مايو 2024 07:40:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

07 مايو 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

17 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

26 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

20 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

13 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

12 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

06 مارس 2024 16:25:47 بحسب Nasdaq GlobeNewswire

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

29 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

07 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

03 يناير 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

22 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

16 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

07 نوفمبر 2023 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease

17 أكتوبر 2023 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

05 أكتوبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

26 سبتمبر 2023 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

11 سبتمبر 2023 12:00:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

08 سبتمبر 2023 16:05:38 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

08 سبتمبر 2023 07:05:56 بحسب Nasdaq GlobeNewswire